Results 81 to 90 of about 1,255,934 (217)
, 2018 Shu-Jun Lu, Xiao-Sheng Zhou, Qi Zheng, Hong-Liang Chen, Yan-Lei Geng Department of Neurology, Binzhou Medical University Hospital, Binzhou, People’s Republic of China Objectives: This study aimed to determine the relationship between the ...
Lu SJ +4 more
core
ALOX15 links lipid metabolism to receptor trafficking in platelet activation
The FEBS Journal, EarlyView.This schematic summarizes known and newly identified mechanisms of thrombin‐mediated platelet activation. In addition to classical thrombin‐induced PAR4 signaling pathways, thrombin activates an ALOX15–HETE–PKCθ–NMT1 signaling cascade that promotes protein myristoylation, facilitates receptor trafficking, and enhances PAR4 surface expression on ...
Yosef Eshetie Amare +2 more
wiley +1 more source
, 2023 P2Y12 is a G-protein-coupled receptor that is activated upon ADP binding. Considering its well-established role in platelet activation, blocking P2Y12 has been used as a therapeutic strategy for antiplatelet aggregation in cardiovascular disease patients.
Emmanuel Boadi Amoafo +4 more
core +1 more source
Testing for Non‐Severe Heritable Platelet Function Disorders
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Heritable platelet function disorders (HPFD) are a diverse group of bleeding disorders characterised by a primary qualitative defect in platelet function rather than platelet number. HPFD may be broadly categorised according to the severity of bleeding, with Glanzmann thrombasthenia and Bernard Soulier syndrome classically considered severe ...
Kate Burley +3 more
wiley +1 more source
, 2017 Mingjuan Liu,1 Ming Yao,1,2 Hanqi Wang,1 Longsheng Xu,1 Ying Zheng,1 Bing Huang,1 Huadong Ni,1 Shijie Xu,1 Xuyan Zhou,1 Qingquan Lian2 1Department of Anesthesiology and Pain Medicine, The First Hospital of Jiaxing, The First Affiliated Hospital of ...
Zheng Y +9 more
core
Frontiers in Pharmacology, 2017 Aims: Dual platelet inhibition using anti-P2Y12 drugs and aspirin is the standard of care in patients after percutaneous coronary interventions (PCI). Prasugrel and ticagrelor have been shown to be more potent than clopidogrel with less high on-treatment
Valentina Forni Ogna +12 more
doaj +1 more source
The Pharmacodynamics of Switching Between P2Y12 Receptor Antagonists
JACC: Cardiovascular Interventions, 2016 The P2Y12 receptor antagonists are key components of the medical and invasive management of coronary artery disease. These agents reduce recurrent cardiovascular events in the setting of acute coronary syndrome (ACS), decrease the incidence of thrombotic events after percutaneous ...
openaire +2 more sources
Journal of Diabetes Investigation, EarlyView.Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim +5 more
wiley +1 more source
Differential effects of P2Y12 inhibition on sleep and glymphatic function in male and female mice
Brain, Behavior, & Immunity - HealthMicroglial P2Y12 receptor is a key regulator of neuroimmune homeostasis, but its role in integrating sleep, glymphatic influx, and microglial dynamics across sexes remains to be further investigated.
Lihan Su +8 more
doaj +1 more source
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 9, Page 1219-1233, November 2026.Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala +13 more
wiley +1 more source